Brought to you by 
SmithKline and Alizyme partner for renzapride development
20 Jun 2000
Executive Summary
Alizyme, a biotech specializing in obesity and gastrointestinal therapeutics, will codevelop and has optioned rights to SmithKline's renzapride compound and its derivatives.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com